Navigation Links
Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
Date:2/25/2009

s evaluated using RECIST (Response Evaluation Criteria in Solid Tumors; an internationally recognized measure of disease progression) in patients with measureable disease showed an overall response rate of 8 percent (one partial response in 13 patients with measureable disease) and a 54 percent disease control rate (six of 13 patients with measureable disease). In comparison, published literature reports overall response rates of 8 to 12 percent in patients treated with docetaxel alone.
  • These data indicate that picoplatin can be safely administered with full-dose docetaxel. Neutropenia was the main hematologic toxicity. Thrombocytopenia was less severe and less frequent with picoplatin administered in combination with docetaxel compared with picoplatin administered alone.
  • These findings confirm and extend earlier Phase 2 results presented at the 20th European Organization for Research and Treatment of Cancer - National Cancer Institute - American Association for Cancer Research (EORTC-NCI-AACR) Symposium on "Molecular Targets and Cancer" in Geneva, Switzerland, in October 2008.

    "The encouraging PSA response rates, time to PSA progression and radiologic responses rates, combined with the promising safety results observed to date, support further development of picoplatin in combination with docetaxel and prednisone in advanced prostate cancer patients," said Robert De Jager, M.D., chief medical officer of Poniard. "We continue to collect and analyze data from this trial and expect to present updated clinical data, including time to disease progression and overall survival, at medical conferences later this year."

    About Picoplatin

    Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date indicate that it has an improved safety profile relative to existing platinum-based cancer therapies
    '/>"/>

    SOURCE Poniard Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
    2. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
    3. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
    4. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
    5. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
    6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
    7. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
    8. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
    9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
    10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
    11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... 22, 2015 Selexis SA, a serial ... Cell Banks (RCBs) used for drug discovery to commercial ... will include Next-Generation Sequencing (NGS) data packages. ... biologic manufacturing by ensuring the integrity of the gene, ...
    (Date:1/22/2015)... Medical Systems (NYSE: VAR ), world leader in ... to sustainability with inclusion on a prestigious list of the ... equipment company among the Corporate Knights Global 100 Most Sustainable ... Davos, Switzerland . "We ...
    (Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
    (Date:12/24/2014)... 2014 “Preparative & Process Chromatography ... Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, ... - Forecasts to 2019” provides a detailed overview ... market trends, and strategies impacting the preparative and ...
    Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4
    ... announced that it has entered into agreement with ... generated by 100 percent,renewable energy resources, through IPL,s ... of fossil-fueled power generation, this,program will better enable ... BST becomes the third-largest customer to participate in ...
    ... objective of the,Alliance is to improve patient care ... marketplace. To celebrate the Alliance, a symposium ... with noted speakers from industry, government,entrepreneurs, venture capitalists ... Gesellschaft. The alliance will take advantage of ...
    ... in Pioneering Field, BETHESDA, Md., Sept. 10 ... of an ownership interest in,ClinResearch GmbH, a global ... adaptive, clinical trials. Headquartered in Cologne, Germany,with more ... 80,adaptive programs over the past seven years. ClinResearch,s ...
    Cached Biology Technology:BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy 2BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy 3BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy 4'Alliance for Medical Devices, Instrumentation and Diagnostics' formed between Fraunhofer Center for Manufacturing Innovation and Boston University 2United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider 2
    (Date:12/17/2014)... Valencell, a leader in performance biometric data sensor technology, ... such as Intel, Jabra, Atlas, and Scosche to develop ... products will be showcased at CES 2015, taking place ... "Our partners choose PerformTek biometrics, because ...
    (Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation is fundamentally ... evident than at international borders. Over the past decade, ... veteran travelers to self process through border control via ... increasing number of airports, seaports, and land borders across ...
    (Date:12/11/2014)... Research and Markets , ... announced the addition of the "Biometrics Market in ... One major trend emerging in this market ... it is important to upgrade biometric solutions to the ...
    Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
    ... outbreaks, wildfire, and forest dieback, may adversely affect people ... The U.S. Geological Survey led a new ... "ecological thresholds" in North America. The report, which was ... authored by a team of federal and academic climate ...
    ... expert David S. Rose will present a lecture at ... You Think You Know...Is Wrong: How New Technologies and ... As part of the Heath Lecture Series at ... will discuss the latest technologies and concepts that are ...
    ... YORK, January 16, 2009 - Researchers at the University of ... adult beta cells have the ability to replicate with the ... was led by Andrew F. Stewart, M.D., a Professor of ... at the University of Pittsburgh School of Medicine. The ...
    Cached Biology News:David Rose to present Howe School lecture on new technologies and business models, Jan. 29 2JDRF-funded researchers discover proteins regulating human beta cell replication 2
    No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
    No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
    12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
    ...
    Biology Products: